title: Genetic Risk Evaluation in Wet Age-Related Macular Degeneration Treatment Response.
abstract: OBJECTIVE
  To evaluate the pharmacogenetic relationship between CFH haplotypes and single nucleotide polymorphisms (SNPs) with response to ranibizumab treatment for neovascular age-related macular degeneration (nAMD).
  
  
  METHODS
  This was a prospective cohort study involving 70 treatment-naive nAMD patients. Patients were genotyped for CFH haplotypes and SNPs in the C3, ARMS2, and mtDNA genes. Visual acuity and central macular thickness were assessed at baseline and during 6 monthly follow-up visits. Multivariate logistic regression was used to determine the association between genotypes and a gain of ≥15 letters at the 6-month endpoint after adjusting for potential confounders.
  
  
  RESULTS
  CFH haplotypes were associated with a gain of ≥15 letters at the 6-month endpoint (p = 0.046). Patients expressing protective haplotypes were more likely to achieve a gain of ≥15 letters relative to the greatly increased risk haplotypes [OR 6.58 (95% CI: 1.37, 31.59)].
  
  
  CONCLUSIONS
  CFH is implicated in nAMD patient treatment response to ranibizumab.
authors.affiliation: Division of Ophthalmology, Department of Surgery, Hamilton Regional Eye Institute, St. Joseph's Healthcare Hamilton, McMaster University, Hamilton, Ont., Canada.
authors.forename: Varun
authors.initials: V
authors.lastname: Chaudhary
authors.forename: Michael
authors.initials: M
authors.lastname: Brent
authors.forename: Wai-Ching
authors.initials: WC
authors.lastname: Lam
authors.forename: Robert
authors.initials: R
authors.lastname: Devenyi
authors.forename: Joshua
authors.initials: J
authors.lastname: Teichman
authors.forename: Michael
authors.initials: M
authors.lastname: Mak
authors.forename: Joshua
authors.initials: J
authors.lastname: Barbosa
authors.forename: Harneel
authors.initials: H
authors.lastname: Kaur
authors.forename: Ronald
authors.initials: R
authors.lastname: Carter
authors.forename: Forough
authors.initials: F
authors.lastname: Farrokhyar
mesh_terms: D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage; D004247:DNA / Q000235:genetics*; D005260:Female; D005451:Fluorescein Angiography; D005500:Follow-Up Studies; D005654:Fundus Oculi; D005787:Gene Frequency; D020022:Genetic Predisposition to Disease; D005838:Genotype; D006801:Humans; D058449:Intravitreal Injections; D008297:Male; D020641:Polymorphism, Single Nucleotide; D011446:Prospective Studies; D000069579:Ranibizumab / Q000008:administration & dosage*; D012307:Risk Factors; D013997:Time Factors; D042461:Vascular Endothelial Growth Factor A; D057135:Wet Macular Degeneration / Q000175:diagnosis / Q000188:drug therapy / Q000235:genetics*
chemical_list: D020533:Angiogenesis Inhibitors; D042461:Vascular Endothelial Growth Factor A; D004247:DNA; D000069579:Ranibizumab